Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Sunitinib"

18:18 EDT 24th April 2014 | BioPortfolio

Matching Channels

None

Matching News

Advanced age should not preclude sunitinib use for mRCC

Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.

Altering sunitinib dosing schedule improves tolerability

Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese res...

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest...

Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCC

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

Human medicines European public assessment report (EPAR): Sutent, sunitinib, Revision: 22, Authorised

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma

Matching PubMed Articles

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction.

Sunitinib is an inhibitor of the multiple receptor tyrosine kinases (RTKs) for cancer therapy. Some sunitinib analogues could prevent neuronal death induced by various neurotoxins. However, the neurop...

Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.

Background: Fluoroquinolones are widely prescribed antibiotics. Ciprofloxacin is a well-known inhibitor of cytochrome P450 CYP3A4 and causes numerous drug interactions that are not found for levofloxa...

Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of suni...

Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis.

There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patien...

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated....

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement